Myriad Genetics, Inc. (MYGN) Given Average Rating of “Hold” by Analysts
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been given a consensus rating of “Hold” by the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $28.90.
A number of equities analysts have issued reports on MYGN shares. Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Sunday, September 17th. Stephens reissued an “overweight” rating and issued a $40.00 price target (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Leerink Swann reissued a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a report on Monday, October 2nd. Morgan Stanley reissued an “underweight” rating and issued a $24.00 price target (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Finally, Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target on the stock in a report on Tuesday, October 17th.
In other Myriad Genetics news, Director Walter Phd Gilbert sold 7,500 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,531 shares of company stock worth $545,826. Insiders own 6.70% of the company’s stock.
Myriad Genetics (MYGN) opened at $35.53 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The stock has a market cap of $2,460.00, a price-to-earnings ratio of 24.01, a price-to-earnings-growth ratio of 2.21 and a beta of 0.24. Myriad Genetics has a fifty-two week low of $15.15 and a fifty-two week high of $37.30.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. The firm had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 EPS. sell-side analysts anticipate that Myriad Genetics will post 1.05 earnings per share for the current fiscal year.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.